Yesterday’s New York Times article about health care reform and the overly inflated cost of the American health care system should ring large and loud alarm bells in the prostate cancer community. This article, along with the recent increasing pressure to halt prostate cancer screening, should put a major scare into the community. Unfortunately, the [...]
The generic drug manufacturing company from India, Sun Pharmaceutical Industries Ltd, has received approval from the U.S. Food and Drug Administration (FDA) to sell a generic version of AstraZeneca's prostate cancer drug Casodex. Casodex (bicalutamide) is an anti-androgen that block the ability of androgens (testosterone) to access the prostate cancer cell and “fuel” them. Used [...]
Researchers at Purdue have developed what they have described as prostate cancer “homing device.” They believe that this treatment modality can improve detection, and allow for the first targeted treatment of prostate cancer. The researchers have synthesized a molecule that finds and penetrates only prostate cancer cells. They have also created imaging agents and therapeutic [...]
A small study out of the Department of Urology, University of Rome, Rome, Italy has demonstrated that a salvage radical prostatectomy is a reasonable treatment option for men with locally recurrent prostate cancer after external beam radiotherapy failure. Despite the traditional belief that surgery can not follow failed radiation treatment, this argument against initial radiotherapy [...]
I have written a fair amount over the life of this blog about the cognitive impairment that many of us experience when we are on an androgen blockade (ADT). I have share my experiences about getting lost on the NYC subway, forgetting where I was going and why I was going there. I also have [...]